Research programme: selective androgen receptor modulators - QuatRx Pharmaceuticals

Drug Profile

Research programme: selective androgen receptor modulators - QuatRx Pharmaceuticals

Alternative Names: SARMs - QuatRx Pharmaceuticals

Latest Information Update: 04 Apr 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator QuatRx Pharmaceuticals
  • Class
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Andropause

Most Recent Events

  • 04 Apr 2008 Discontinued - Preclinical for Andropause in Finland (unspecified route)
  • 16 May 2005 Hormos Medical has been acquired and merged into QuatRx Pharmaceuticals
  • 11 Jul 2001 Preclinical development for Andropause in Finland (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top